In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery.
The worldwide TB structural genomics initiative has identified several new drug targets for Mycobacterium tuberculosis (M. tb). Dihydrofolate reductase (DHFR) catalyzes the NADPH-dependent reduction of dihydrofolate to tetrahydrofolate that is essential for DNA synthesis. Inhibition of its activity leads to arrest of DNA synthesis and hence cell death. Thus, M. tb DHFR (mtDHFR) is an attractive novel drug target for developing anti-TB drugs. Structural comparison of mtDHFR and human DHFR (hDHFR) reveals key differences in the active sites. These differences can be exploited for the design of selective inhibitors for mtDHFR. Based on the recently determined high resolution crystal structure of mtDHFR complexed with known inhibitor methotrexate (MTX) and cofactor NADPH, a tri-peptide inhibitor has been identified using a structure-based drug design approach. Docking studies indicate that the designed tripeptide inhibitor has a high potency (K (d) = 1.78 nM) and is a selective (approximately 120 fold over hDHFR) inhibitor for mtDHFR. Hence, the tripeptide is a suitable lead compound for the development of novel anti-TB drugs.
Kumar
Manoj
M
Department of Biophysics, All India Institute of Medical Sciences, New Delhi 110029, India.
Vijayakrishnan
Rajakrishnan
R
Subba Rao
Gita
G
D000595:Amino Acid Sequence; D000995:Antitubercular Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D001665:Binding Sites; D019295:Computational Biology / Q000379:methods*; D018360:Crystallography, X-Ray; D015195:Drug Design; D005493:Folic Acid Antagonists / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D006860:Hydrogen Bonding / Q000187:drug effects; D008024:Ligands; D008727:Methotrexate / Q000737:chemistry / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D056004:Molecular Dynamics Simulation; D008969:Molecular Sequence Data; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000201:enzymology*; D009952:Ornithine / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology; D010455:Peptides / Q000737:chemistry / Q000145:classification* / Q000494:pharmacology*; D011622:Pterins / Q000737:chemistry / Q000494:pharmacology; D015203:Reproducibility of Results; D013379:Substrate Specificity / Q000187:drug effects; D013762:Tetrahydrofolate Dehydrogenase / Q000378:metabolism*; D014227:Triazines / Q000737:chemistry / Q000494:pharmacology; D014376:Tuberculosis / Q000188:drug therapy
D000995:Antitubercular Agents; D005493:Folic Acid Antagonists; D008024:Ligands; D010455:Peptides; D011622:Pterins; D014227:Triazines; C085590:N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine; C006201:BRL 6231; D009952:Ornithine; D013762:Tetrahydrofolate Dehydrogenase; D008727:Methotrexate
Clin Infect Dis. 2003 Jan 15;36(Suppl 1):S24-30
12516027
Nat Struct Mol Biol. 2006 May;13(5):408-13
16648861
J Comput Aided Mol Des. 1994 Jun;8(3):243-56
7964925
Exp Parasitol. 1997 Nov;87(3):222-8
9371087
Biochemistry. 1997 Nov 11;36(45):13897-903
9374868
N Engl J Med. 2007 Feb 15;356(7):656-9
17301295
J Mol Biol. 2000 Jan 14;295(2):307-23
10623528
Org Biomol Chem. 2003 Mar 21;1(6):960-4
12929634
Biochemistry. 1997 Apr 15;36(15):4399-411
9109647
J Comput Chem. 2003 Oct;24(13):1549-62
12925999
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
10592235
BMJ. 2002 Nov 30;325(7375):1282-6
12458250
Lancet. 1999 May 1;353(9163):1469-75
10232312
J Med Chem. 2003 Jun 5;46(12):2287-303
12773034
FEMS Microbiol Lett. 2004 Mar 12;232(1):101-5
15019741
Bioorg Med Chem Lett. 2005 Apr 1;15(7):1943-7
15780638
Arch Intern Med. 2003 May 12;163(9):1009-21
12742798
FASEB J. 1990 May;4(8):2441-52
2185970
J Comput Aided Mol Des. 1998 Jul;12(4):309-23
9777490
Methods Mol Biol. 2008;494:1-8
18726565
J Biomol Struct Dyn. 2008 Feb;25(4):377-85
18092832
Chem Biol Drug Des. 2008 Nov;72(5):444-9
19012578
J Comput Aided Mol Des. 1994 Oct;8(5):623-32
7876904